Grippe aviaire et transmission chez l'homme (2006) Delvallée/Documentation

1. FAO, OIE and OMS (2005). "Lignes directrices sur la prévention et le contrôle de l'influenza aviaire." Organisation des Nations Unies pour l'alimentation et l'agriculture-Organisation Internationale des épizooties- Organisation Mondiale de la Santé.

2. OMS (2003). "Production of pilot lots of inactivated influenza vaccines from reassortants derived from avian influenza viruses. Interim biosafety risk assessment." Organisation Mondiale de la Santé.

3. OMS (2004). "Exposures that may have put a person at risk of becoming infected with influenza A(H5N1)." Organisation Mondiale de la Santé.

4. OMS (2005). "WHO guidance on development of influenza vaccine reference viruses by reverse genetics." Organisation Mondiale de la Santé.

5. OMS (2005). "Recommended laboratory tests to identify avian influenza A virus in specimens from humans." Organisation Mondiale de la Santé.

6. OMS (2006). "Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO." Organisation Mondiale de la Santé.

7. OMS (2006). "Avian influenza, including influenza A (H5N1), in humans : WHO interim infection control guideline for health care facilities." Organisation Mondiale de la Santé.

8. UPMC (2005). "Peramivir : Single Dose Prophylaxis for Flu?" Center for Biosecurity of UPMC, for a briefing on Capitol Hill.

9. Abed Y, Hardy I, Li Y and Boivin G (2002). "Divergent evolution of hemagglutinin and neuraminidase genes in recent influenza A:H3N2 viruses isolated in Canada." Journal of medical virology67(4) : 589-595.

10. Al Faress S, Cartet G, Ferraris O, Norder H, Valette M and Lina B (2005). "Divergent genetic evolution of hemagglutinin in influenza A H1N1 and A H1N2 subtypes isolated in the south-France since the winter of 2001-2002." J Clin Virol33(3) : 230-6.

11. Alexander DJ, Van RK and Pensaert M (2000). "A review of avian influenza in different bird species." Veterinary microbiology : (Amsterdam)74(1-2) : 3-13.

12. Amonsin A, Payungporn S, Theamboonlers A, Thanawongnuwech R, Suradhat S, Pariyothorn N, Tantilertcharoen R, Damrongwantanapokin S, Buranathai C, Chaisingh A, Songserm T and Poovorawan Y (2005). "Genetic characterization of H5N1 influenza A viruses isolated from zoo tigers in Thailand." Virology 344(2) : 480-491.

13. Apisarnthanarak A, Erb S, Stephenson I, Katz JM, Chittaganpitch M, Sangkitporn S, Kitphati R, Thawatsupha P, Waicharoen S, Pinitchai U, Apisarnthanarak P, Fraser VJ and Mundy LM (2005). "Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to Avian influenza (H5N1) in a tertiary care center." Clin Infect Dis 40(2) : e16-8.

14. Apisarnthanarak A, Kitphati R, Thongphubeth K, Patoomanunt P, Anthanont P, Auwanit W, Thawatsupha P, Chittaganpitch M, Saeng-Aroon S, Waicharoen S, Apisarnthanarak P, Storch GA, Mundy LM and Fraser VJ (2004). "Atypical avian influenza (H5N1)." Emerg Infect Dis 10(7) : 1321-4.

15. Aymard M, Gerentes L and Kessler N (1999). "Place des anticorps antineuraminidase dans la protection contre la grippe. (Role for antibody to neuraminidase in protecting against influenza)." La Semaine des hôpitaux de Paris75(23-24) : 933-941.

16. Babai I, Barenholz Y, Zakay-Rones Z, Greenbaum E, Samira S, Hayon I, Rochman M and Kedar E (2001). "A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective antineuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains." Vaccine20(3-4) : 505-15.

17. Baigent SJ and McCauley JW (2001). "Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture." Virus Res79(1-2) : 177-85.

18. Baigent SJ and McCauley JW (2003). "Influenza type A in humans, mammals and birds : determinants of virus virulence, host-range and interspecies transmission." Bioessays25(7) : 657-71.

19. Banks J, Speidel E and Alexander DJ (1998). "Characterisation of an avian influenza A virus isolated from a human : is an intermediate host necessary for the emergence of pandemic influenza viruses?" Archives of virology143(4) : 781-787.

20. Banks J, Speidel ES, Moore E, Plowright L, Piccirillo A, Capua I, Cordioli P, Fioretti A and Alexander DJ (2001). "Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy." Archives of virology146(5) : 963-973.

21. Bantia S, Arnold CS, Parker CD, Upshaw R and Chand P (2005). "Anti-influenza virus activity of peramivir in mice with single intramuscular injection." Antiviral Res.

22. Beby-Defaux A, Giraudeau G, Bouguermouh S and Agius G (2003). "La grippe humaine : aspects virologiques, épidémiologie et diagnostic virologique. (Influenza : virological aspects, epidemiology and virological diagnosis)." Médecine et maladies infectieuses33(3) : 134-142.

23. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, de Jong MD, Lochindarat S, Nguyen TK, Nguyen TH, Tran TH, Nicoll A, Touch S and Yuen KY (2005). "Avian influenza A (H5N1) infection in humans." N Engl J Med 353(13) : 1374-85.

24. Bennink JR and Palmore TN (2004). "The promise of siRNAs for the treatment of influenza." Trends Mol Med10(12) : 571-4.

25. Ben-Yehuda A, Joseph A, Barenholz Y, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Galprin I, Gluck R, Zurbriggen R and Kedar E (2003). "Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents." Vaccine 21(23) : 3169-78.

26. Ben-Yehuda A, Joseph A, Zeira E, Even-Chen S, Louria-Hayon I, Babai I, Zakay-Rones Z, Greenbaum E, Barenholz Y and Kedar E (2003). "Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults." J Med Virol69(4) : 560-7.

27. Boibieux A, Bouhour D, Biron F, Chidiac C and Peyramond D (1998). "La grippe aviaire de Hong Kong. (Avian influenza in Hong Kong)." Médecine et maladies infectieuses28(2) : 193-194.

28. Bridges CB, Katz JM, Seto WH, Chan PKS, Tsang D, Ho W, Mak KH, Lim W, Tam JS, Clarke M, Williams SG, Mounts AW, Bresee JS, Conn LA, Rowe T, Hu-Primmer J, Abernathy RA, Xiuhua LU, Cox NJ and Fukuda K (2000). "Risk of influenza A (H5N1) infection among health care workers exposed to patients with influenza A (H5N1), Hong Kong." The Journal of infectious diseases 181(1) : 344-348.

29. Bridges CB, Lim W, Hu-Primmer J, Sims L, Fukuda K, Mak KH, Rowe T, Thompson WW, Conn L, Lu X, Cox NJ and Katz JM (2002). "Risk of influenza A (H5N1) infection among poultry workers, Hong Kong, 1997-1998." J Infect Dis185(8) : 1005-10.

30. Bright RA, Cho DS, Rowe T and Katz JM (2003). "Mechanisms of pathogenicity of influenza A (H5N1) viruses in mice." Avian Dis47(3 Suppl) : 1131-4.

31. Bright RA, Medina MJ, Xu X, Perez-Oronoz G, Wallis TR, Davis XM, Povinelli L, Cox NJ and Klimov AI (2005). "Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005 : a cause for concern." Lancet366(9492) : 1175-81.

32. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, Xu KM, Lim W, Webster RG, Yuen KY, Peiris JS and Guan Y (2005). "Human Infection with an Avian H9N2 Influenza A Virus in Hong Kong in 2003." J Clin Microbiol43(11) : 5760-7.

33. Cappucci DT, Jr., Johnson DC, Brugh M, Smith TM, Jackson CF, Pearson JE and Senne DA (1985). "Isolation of avian influenza virus (subtype H5N2) from chicken eggs during a natural outbreak." Avian Dis29(4) : 1195-200.

34. Capua I and Alexander DJ (2002). "Avian influenza and human health." Acta tropica83(1) : 1-6.

35. Castrucci MR, Donatelli I, Sidoli L, Barigazzi G, Kawaoka Y and Webster RG(1993). "Genetic reassortment between avian and human influenza A viruses in italian pigs." Virology : (New York, NY)193(1) : 503-506.

36. Chan PK (2002). "Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997." Clin Infect Dis34 Suppl 2 : S58-64.

37. Chand P, Babu YS, Bantia S, Rowland S, Dehghani A, Kotian PL, Hutchison TL, Ali S, Brouillette W, El-Kattan Y and Lin TH (2004). "Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives." J Med Chem47(8) : 1919-29.

38. Chand P, Bantia S, Kotian PL, El-Kattan Y, Lin TH and Babu YS (2005). "Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo." Bioorg Med Chem13(12) : 4071-7.

39. Cheng X, Liu J, He J and Shan F (2002). "Virological and serological surveys for H9N2 subtype of influenza A virus in chickens and men in Shenzhen city." Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi16(4) : 319-21.

40. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, Gordon S, Guan Y and Peiris JS (2002). "Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses : a mechanism for the unusual severity of human disease?" Lancet360(9348) : 1831-7.

41. Choi YK, Nguyen TD, Ozaki H, Webby RJ, Puthavathana P, Buranathal C, Chaisingh A, Auewarakul P, Hanh NT, Ma SK, Hui PY, Guan Y, Peiris JS and Webster RG (2005). "Studies of H5N1 influenza virus infection of pigs by using viruses isolated in Vietnam and Thailand in 2004." J Virol 79(16) : 10821-5.

42. Chokephaibulkit K, Uiprasertkul M, Puthavathana P, Chearskul P, Auewarakul P, Dowell SF and Vanprapar N (2005). "A child with avian influenza A (H5N1) infection." Pediatr Infect Dis J 24(2) : 162-6.

43. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, Chunsuthiwat S, Sawanpanyalert P, Kijphati R, Lochindarat S, Srisan P, Suwan P, Osotthanakorn Y, Anantasetagoon T, Kanjanawasri S, Tanupattarachai S, Weerakul J, Chaiwirattana R, Maneerattanaporn M, Poolsavathitikool R, Chokephaibulkit K, Apisarnthanarak A and Dowell SF (2005). "Human disease from influenza A (H5N1), Thailand, 2004." Emerg Infect Dis 11(2) : 201-9.

44. Claas ECJ, De JJC, Van BR, Rimmelzwaan GF and Osterhaus ADME (1998). "Human influenza virus A/HongKong/156/97 (H5N1) infection." Vaccine16(9-10) : 977-978.

45. Claas ECJ, Van RK and Pensaert M (2000). "Pandemic influenza is a zoonosis, as it requires introduction of avian-like gene segments in the human population." Veterinary microbiology : (Amsterdam)74(1-2) : 133-139.

46. Coiras MT, Aguilar JC, Galiano M, Carlos S, Gregory V, Lin YP, Hay A and Perez-Brena P (2001). "Rapid molecular analysis of the haemagglutinin gene of human influenza A H3N2 viruses isolated in Spain from 1996 to 2000." Archives of virology146(11) : 2133-2147.

47. Collins RA, Ko L-S, So K-L, Ellis T, Lau L-T and Cheung HOIYUA (2002). "Detection of highly pathogenic and low pathogenic avian influenza subtype H5 (Eurasian lineage) using NASBA." Journal of virological methods103(2) : 213-225.

48. Cooper N, Sutton AJ, Abrams KR, Wailoo A, Turner DA, Nicholson KG and Hansen L (2003). "Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B : systematic review and meta-analyses of randomised controlled trials. Commentary." BMJ. British medical journal : (International ed.)326(7401) : 1235-1240.

49. Daems R, Del Giudice G and Rappuoli R (2005). "Anticipating crisis : Towards a pandemic flu vaccination strategy through alignment of public health and industrial policy." Vaccine.

De 50 à 99

50. de Bruijn IA, Nauta J, Cramer WC, Gerez L and Palache AM (2005). "Clinical experience with inactivated, virosomal influenza vaccine." Vaccine23 Suppl 1 : S39-49.

51. de Jong MD, Bach VC, Phan TQ, Vo MH, Tran TT, Nguyen BH, Beld M, Le TP, Truong HK, Nguyen VV, Tran TH, Do QH and Farrar J (2005). "Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma." N Engl J Med352(7) : 686-91.

52. de Jong MD and Hien TT (2006). "Avian influenza A (H5N1)." J Clin Virol35(1) : 2-13.

53. de Jong MD, Tran TT, Truong HK, Vo MH, Smith GJ, Nguyen VC, Bach VC, Phan TQ, Do QH, Guan Y, Peiris JS, Tran TH and Farrar J (2005). "Oseltamivir resistance during treatment of influenza A (H5N1) infection." N Engl J Med 353(25) : 2667-72.

54. Demicheli V, Jefferson T, Rivetti D and Deeks J (2000). "Prevention and early treatment of influenza in healthy adults." Vaccine18(11-12) : 957-1030.

55. Deshpande KL, Naeve CW and Webster RG (1985). "The neuraminidases of the virulent and avirulent A/chicken/Pennsylvania/83 (H5N2) influenza A viruses : sequence and." Virology147(1) : 49-60.

56. Dreitlein WB, Maratos J and Brocavich J (2001). "Zanamivir and oseltamivir : Two new options for the treatment and prevention of Influenza." Clinical therapeutics23(3) : 327-355.

57. Dutkowski R, Thakrar B, Froehlich E, Suter P, Oo C and Ward P (2003). "Safety and pharmacology of oseltamivir in clinical use." Drug safety26(11) : 787-801.

58. Ellis JS and Zambon MC (2001). "Combined PCR-heteroduplex mobility assay for detection and differentiation of influenza A viruses from different animal species." Journal of clinical microbiology39(11) : 4097-4102.

59. Enserink M (2005). "Avian influenza. 'Pandemic vaccine' appears to protect only at high doses." Science309(5737) : 996.

60. Enserink M and Kaiser J (2004). "Virology. Avian flu finds new mammal hosts." Science305(5689) : 1385.

61. Faulkner L, Buchan G, Slobbe L, Lockhart E, Wales J, Wilson M and Baird M(2003). "Influenza hemagglutinin peptides fused to interferon gamma and encapsulated in liposomes protects mice against influenza infection." Vaccine21(9-10) : 932-9.

62. Fedson DS (2003). "Vaccination for pandemic influenza and severe acute respiratory syndrome : Common issues and concerns." Clinical infectious diseases36(12) : 1562-1563.

63. Fedson DS (2003). "Pandemic influenza and the global vaccine supply." Clinical infectious diseases36(12) : 1552-1561.

64. Fedson DS (2005). "Preparing for pandemic vaccination : an international policy agenda for vaccine development." J Public Health Policy26(1) : 4-29.

65. Fleming DM (2001). "Managing influenza : Amantadine, rimantadine and beyond." International journal of clinical practice : (Esher)55(3) : 189-195.

66. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, Smith D, Rimmelzwaan GF, Olsen B and Osterhaus AD (2005). "Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls." J Virol79(5) : 2814-22.

67. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M and Osterhaus AD (2004). "Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome." Proc Natl Acad Sci U S A 101(5) : 1356-61.

68. Gambaryan A, Tuzikov A, Pazynina G, Bovin N, Balish A and Klimov A (2005). "Evolution of the receptor binding phenotype of influenza A (H5) viruses." Virology.

69. Gani R (2005). "Potential Impact of Antiviral Drug Use during Influenza Pandemic." Emerg Infect Dis11(9) : 1355-62.

70. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, Matsuoka Y, Robbins PD, Swayne DE, Donis RO, Katz JM, Barratt-Boyes SM and Gambotto A (2006). "Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization." J Virol 80(4) : 1959-64.

71. Ge Q, Eisen HN and Chen J (2004). "Use of siRNAs to prevent and treat influenza virus infection." Virus Res102(1) : 37-42.

72. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN and Chen J (2004). "Inhibition of influenza virus production in virus-infected mice by RNA interference." Proc Natl Acad Sci U S A101(23) : 8676-81.

73. Gibbs MJ, Armstrong JS and Gibbs AJ (2001). "Recombination in the hemagglutinin gene of the 1918 "spanish flu"." Science : (Washington, D.C.)293(5536) : 1842-1845.

74. Girard MP, Cherian T, Pervikov Y and Kieny MP (2005). "A review of vaccine research and development : Human acute respiratory infections." Vaccine23(50) : 5708-24.

75. Govorkova EA, Rehg JE, Krauss S, Yen HL, Guan Y, Peiris M, Nguyen TD, Hanh TH, Puthavathana P, Long HT, Buranathai C, Lim W, Webster RG and Hoffmann E (2005). "Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004." J Virol 79(4) : 2191-8.

76. Grose C and Chokephaibulkit K (2004). "Avian influenza virus infection of children in Vietnam and Thailand." Pediatr Infect Dis J23(8) : 793-4.

77. Gubareva LV (2004). "Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors." Virus Res103(1-2) : 199-203.

78. Hannoun C (2001). "Sur la piste du virus de la grippe espagnole (1918-1919). (On the trail of Spanish influenza virus)." Virologie : (Montrouge)5(1) : 45-52.

79. Hatta M, Peng GAO, Halfmann P and Kawaoka Y (2001). "Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses." Science : (Washington, D.C.)293(5536) : 1840-1842.

80. Hayden F and Croisier A (2005). "Transmission of avian influenza viruses to and between humans." J Infect Dis192(8) : 1311-4.

81. Hehme N, Engelmann H, Kuenzel W, Neumeier E and Saenger R (2004). "Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use." Virus Res103(1-2) : 163-71.

82. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE and Monto AS (2004). "Influenza viruses resistant to the antiviral drug oseltamivir : transmission studies in ferrets." J Infect Dis190(9) : 1627-30.

83. Hilleman MR (2002). "Realities and enigmas of human viral influenza : pathogenesis, epidemiology and control." Vaccine20(25-26) : 3068-3087.

84. Hinshaw VS, Webster RG, Easterday BC and Bean WJ, Jr. (1981). "Replication of avian influenza A viruses in mammals." Infect Immun34(2) : 354-61.

85. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, Stephenson I, Bright RA, Katz JM, Mittal SK and Sambhara S (2006). "Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice." Lancet367(9509) : 475-81.

86. Hoffmann E, Krauss S, Perez D, Webby R and Webster RG (2002). "Eight-plasmid system for rapid generation of influenza virus vaccines." Vaccine20(25-26) : 3165-70.

87. Hoffmann E, Neumann G, Kawaoka Y, Hobom G and Webster RG (2000). "A DNA transfection system for generation of influenza A virus from eight plasmids." Proc Natl Acad Sci U S A97(11) : 6108-13.

88. Horimoto T and Kawaoka Y (1994). "Reverse genetics provides direct evidence for a correlation of hemagglutinin cleavability and virulence of an avian influenza A virus." Journal of virology68(5) : 3120-3128.

89. Horimoto T, Takada A, Fujii K, Goto H, Hatta M, Watanabe S, Iwatsuki-Horimoto K, Ito M, Tagawa-Sakai Y, Yamada S, Ito H, Ito T, Imai M, Itamura S, Odagiri T, Tashiro M, Lim W, Guan Y, Peiris M and Kawaoka Y (2005). "The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate." Vaccine.

90. Hualan C, Subbarao K, Swayne D, Qi C, Xiuhua LU, Katz J, Cox N and Matsuoka Y (2003). "Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate." Vaccine21(17-18) : 1974-1979.

91. Huckriede A, Bungener L, Stegmann T, Daemen T, Medema J, Palache AM and Wilschut J (2005). "The virosome concept for influenza vaccines." Vaccine 23 Suppl 1 : S26-38.

92. Hulse DJ, Webster RG, Russell RJ and Perez DR (2004). "Molecular determinants within the surface proteins involved in the pathogenicity of H5N1 influenza viruses in chickens." J Virol78(18) : 9954-64.

93. Ilyushina NA, Govorkova EA and Webster RG (2005). "Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia." Virology341(1) : 102-6.

94. Institut Pasteur, Réseau national de santé publique, Groupes régionaux d'observation de la grippe, Réseau Sentinelles de l'INSERM and Direction générale de la Santé (1998). "Données sur la grippe à virus A (H5N1) à Hong Kong et sur le début de grippe à virus A (H3N2) en France." Bulletin Epidemiologique Hebdomadaire 8 : 31.

95. Ison MG, Gnann JW, Jr., Nagy-Agren S, Treannor J, Paya C, Steigbigel R, Elliott M, Weiss HL and Hayden FG (2003). "Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza." Antivir Ther8(3) : 183-90.

96. Iwasaki T, Itamura S, Nishimura H, Sato Y, Tashiro M, Hashikawa T and Kurata T (2004). "Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation." Acta Neuropathol (Berl)108(6) : 485-92.

97. Izurieta HS, Haber P, Wise RP, Iskander J, Pratt D, Mink C, Chang S, Braun MM and Ball R (2005). "Adverse events reported following live, cold-adapted, intranasal influenza vaccine." Jama294(21) : 2720-5.

98. Kaiser L (2001). "Inhibiteurs de la neuraminidase et traitement de la grippe : un bénéfice au-delà de la résolution des symptômes ? : Maladies infectieuses. (Treatment of Influenza with neuraminidase inhibitors : is there a benefit beyoud symptom resolution ?)." Médecine et hygiène59(2369) : 2296-2300 [3 ].

99. Kaji M, Fukuda T, Tanaka M and Aizawa H (2005). "A side effect of neuraminidase inhibitor in a patient with liver cirrhosis." J Infect Chemother11(1) : 41-3.

De 100 à 149

100. Karcher F and Buchow H (2002). "Plan de préparation et réponse à la pandémie de grippe au niveau de la Communauté européenne." Eurosurveillance - Bulletin Europeen Sur Les Maladies Transmissibles7(11) : 166-168.

101. Katz JM, Lim W, Bridges CB, Rowe T, Hu-Primmer J, Lu X, Abernathy RA, Clarke M, Conn L, Kwong H, Lee M, Au G, Ho YY, Mak KH, Cox NJ and Fukuda K (1999). "Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts." J Infect Dis 180(6) : 1763-70.

[102] ↑ Kawaoka Y, Krauss S and Webster RG (1989). "Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics." Journal of Virology63(11) : 4603-4608.

103. Keawcharoen J, Oraveerakul K, Kuiken T, Fouchier RA, Amonsin A, Payungporn S, Noppornpanth S, Wattanodorn S, Theambooniers A, Tantilertcharoen R, Pattanarangsan R, Arya N, Ratanakorn P, Osterhaus DM and Poovorawan Y (2004). "Avian influenza H5N1 in tigers and leopards." Emerg Infect Dis 10(12) : 2189-91.

104. Kida H, Ito T, Yasuda J, Shimizu Y, Itakura C, Shortridge KF, Kawaoka Y and Webster RG (1994). "Potential for transmission of avian influenza viruses to pigs." Journal of general virology75(p.9) : 2183-2188.

105. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawakami C, Kimura K, Hayden FG, Sugaya N and Kawaoka Y (2004). "Resistant influenza A viruses in children treated with oseltamivir : descriptive study." Lancet364(9436) : 759-65.

106. Kobasa D, Kodihalli S, Luo M, Castrucci MR, Donatelli I, Suzuki Y, Suzuki T and Kawaoka Y (1999). "Amino acid residues contributing to the substrate specificity of the influenza A virus neuraminidase." J Virol73(8) : 6743-51.

107. Kobasa D, Takada A, Shinya K, Hatta M, Halfmann P, Theriault S, Suzuki H, Nishimura H, Mitamura K, Sugaya N, Usui T, Murata T, Maeda Y, Watanabe S, Suresh M, Suzuki T, Suzuki Y, Feldmann H and Kawaoka Y (2004). "Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus." Nature 431(7009) : 703-7.

[108] ↑ Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A and Bosman A (2004). "Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands." Lancet 363(9409) : 587-93.

109. Kuiken T, Rimmelzwaan G, van Riel D, van Amerongen G, Baars M, Fouchier R and Osterhaus A (2004). "Avian H5N1 influenza in cats." Science 306(5694) : 241.

110. Kuiken T, Rimmelzwaan GF, Van Amerongen G and Osterhaus AD (2003). "Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis)." Vet Pathol40(3) : 304-10.

111. Laver G and Garman E (2002). "Pandemic influenza : its origin and control." Microbes and infection4(13) : 1309-1316.

112. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, Nguyen KH, Pham ND, Ngyen HH, Yamada S, Muramoto Y, Horimoto T, Takada A, Goto H, Suzuki T, Suzuki Y and Kawaoka Y (2005). "Avian flu : isolation of drug-resistant H5N1 virus." Nature 437(7062) : 1108.

113. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG and Webster RG (2000). "The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99." Antiviral research48(2) : 101-115.

114. Li KS, Guan Y, Wang J, Smith GJ, Xu KM, Duan L, Rahardjo AP, Puthavathana P, Buranathai C, Nguyen TD, Estoepangestie AT, Chaisingh A, Auewarakul P, Long HT, Hanh NT, Webby RJ, Poon LL, Chen H, Shortridge KF, Yuen KY, Webster RG and Peiris JS (2004). "Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia." Nature 430(6996) : 209-13.

115. Li S, Perdue ML, Patzer E, Brown F and Gust I (2002). "Seed viruses containing novel avian HA and NA antigens for prevention against potential influenza pandemic." Developments in biologicals110 : 135-141.

116. Li Y, Lin Z, Shi J, Qi Q, Deng G, Li Z, Wang X, Tian G and Chen H (2006). "Detection of Hong Kong 97-like H5N1 influenza viruses from eggs of Vietnamese waterfowl." Arch Virol(Mar 13).

117. Li Z, Chen H, Jiao P, Deng G, Tian G, Li Y, Hoffmann E, Webster RG, Matsuoka Y and Yu K (2005). "Molecular basis of replication of duck H5N1 influenza viruses in a mammalian mouse model." J Virol79(18) : 12058-64.

118. Liem NT and Lim W (2005). "Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004." Emerg Infect Dis11(2) : 210-5.

119. Lin YP, Shaw M, Gregory V, Cameron K, Lim W, Klimov A, Subbarao K, Guan Y, Krauss S, Shortridge K, Webster R, Cox N and Hay A (2000). "Avian-to-human transmission of H9N2 subtype influenza A viruses : relationship between H9N2 and H5N1 human isolates." Proc Natl Acad Sci U S A97(17) : 9654-8.

120. Lindstrom SE, Cox NJ and Klimov A (2004). "Genetic analysis of human H2N2 and early H3N2 influenza viruses, 1957-1972 : evidence for genetic divergence and multiple reassortment events." Virology328(1) : 101-19.

121. Lipatov AS, Andreansky S, Webby RJ, Hulse DJ, Rehg JE, Krauss S, Perez DR, Doherty PC, Webster RG and Sangster MY (2005). "Pathogenesis of Hong Kong H5N1 influenza virus NS gene reassortants in mice : the role of cytokines and B- and T-cell responses." J Gen Virol86(Pt 4) : 1121-30.

122. Lipatov AS, Webby RJ, Govorkova EA, Krauss S and Webster RG (2005). "Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model." J Infect Dis191(8) : 1216-20.

123. Luke CJ and Subbarao K (2006). "Vaccines for pandemic influenza." Emerg Infect Dis12(1).

124. Luscher-Mattli M (2000). "Influenza chemotherapy : a review of the present state of art and of new drugs in development : Brief Review." Archives of virology145(11) : 2233-2248.

125. Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY and Tucker SP (2005). "Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza." J Med Chem 48(8) : 2964-71.

126. Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY and Tucker SP (2004). "Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen." Antimicrob Agents Chemother 48(12) : 4542-9.

127. Maines TR, Lu XH, Erb SM, Edwards L, Guarner J, Greer PW, Nguyen DC, Szretter KJ, Chen LM, Thawatsupha P, Chittaganpitch M, Waicharoen S, Nguyen DT, Nguyen T, Nguyen HH, Kim JH, Hoang LT, Kang C, Phuong LS, Lim W, Zaki S, Donis RO, Cox NJ, Katz JM and Tumpey TM (2005). "Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals." J Virol 79(18) : 11788-800.

128. Marsh GA and Tannock GA (2005). "The role of reverse genetics in the development of vaccines against respiratory viruses." Expert Opin Biol Ther5(3) : 369-80.

129. Masuda H, Suzuki H, Oshitani H, Saito R, Kawasaki S, Nishikawa M and Satoh H (2000). "Incidence of amantadine-resistant influenza A viruses in sentinel surveillance sites and nursing homes in Niigata, Japan." Microbiology and immunology44(10) : 833-839.

130. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA and Klenk HD (2004). "Human and avian influenza viruses target different cell types in cultures of human airway epithelium." Proc Natl Acad Sci U S A101(13) : 4620-4.

131. McClellan K and Perry CM (2001). "Oseltamivir : A review of its use in influenza." Drugs : (Basel)61(2) : 263-283.

132. McGeer AJ, Lee W, Loeb M, Simor AE, McArthur M, Green K, Benjamin JH and Gardner C (2004). "Adverse effects of amantadine and oseltamivir used during respiratory outbreaks in a center for developmentally disabled adults." Infect Control Hosp Epidemiol25(11) : 955-61.

133. McKimm-Breschkin JL (2005). "Management of influenza virus infections with neuraminidase inhibitors : detection, incidence, and implications of drug resistance." Treat Respir Med4(2) : 107-16.

134. McNicholl IR and McNicholl JJ (2001). "Neuraminidase inhibitors : Zanamivir and oseltamivir." (The) Annals of pharmacotherapy35(1) : 57-70.

135. Meijer A, Valette M, Manuguerra JC, Perez-Brena P, Paget J, Brown C and van der Velden K (2005). "Implementation of the community network of reference laboratories for human influenza in Europe." J Clin Virol34(2) : 87-96.

136. Mishin VP, Hayden FG and Gubareva LV (2005). "Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors." Antimicrob Agents Chemother49(11) : 4515-20.

137. Monto AS, Osterhaus ADME, Palache AM, Peiris JSM, Savy VL and StÖHr K(2003). "The role of antivirals in the control of influenza." Vaccine21(16) : 1796-1800.

138. Moscona A (2005). "Neuraminidase inhibitors for influenza." N Engl J Med353(13) : 1363-73.

139. Mounts AW, Kwong H, Izurieta HS, Ho Y, Au T, Lee M, Buxton Bridges C, Williams SW, Mak KH, Katz JM, Thompson WW, Cox NJ and Fukuda K (1999). "Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997." J Infect Dis 180(2) : 505-8.

140. Neumann G, Fujii K, Kino Y and Kawaoka Y (2005). "An improved reverse genetics system for influenza A virus generation and its implications for vaccine production." Proc Natl Acad Sci U S A102(46) : 16825-9.

141. Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G and Kawaoka Y (1999). "Generation of influenza A viruses entirely from cloned cDNAs." Proc Natl Acad Sci U S A 96(16) : 9345-50.

142. Neumann G, Whitt MA and Kawaoka Y (2002). "A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?" J Gen Virol83(Pt 11) : 2635-62.

143. Ng EK, Cheng PK, Ng AY, Hoang TL and Lim WW (2005). "Influenza A H5N1 detection." Emerg Infect Dis11(8) : 1303-5.

144. Nicholson KG, Colegate AE, Podda A, Stephenson L, Wood J, Ypma E and Zambon MC (2001). "Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine : a randomised trial of two potential vaccines against H5N1 influenza." Lancet : (British edition)357(9272) : 1937-1943.

145. Nicolson C, Major D, Wood JM and Robertson JS (2005). "Generation of influenza vaccine viruses on Vero cells by reverse genetics : an H5N1 candidate vaccine strain produced under a quality system." Vaccine23(22) : 2943-52.

146. Noah DL and Krug RM (2005). "Influenza virus virulence and its molecular determinants." Adv Virus Res65 : 121-45.

147. Nordstrom BL, Oh K, Sacks ST and L'Italien GJ (2004). "Skin reactions in patients with influenza treated with oseltamivir : a retrospective cohort study." Antivir Ther9(2) : 187-95.

148. Nwe N, He Q, Damrongwatanapokin S, Du Q, Manopo I, Limlamthong Y, Fenner BJ, Spencer L and Kwang J (2006). "Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture." BMC Microbiol6 : 16.

149. Olsen SJ, Ungchusak K, Sovann L, Uyeki TM, Dowell SF, Cox NJ, Aldis W and Chunsuttiwat S (2005). "Family clustering of avian influenza A (H5N1)." Emerg Infect Dis11(11) : 1799-1801.

DE 150 à 199

150. OMS (2005). "Vaccins antigrippaux." Bulletin Epidemiologique Hebdomadaire33 : 279-287.

151. Oxford J (2005). "Oseltamivir in the management of influenza." Expert Opin Pharmacother6(14) : 2493-500.

152. Oxford JS, Bossuyt S, Balasingam S, Mann A, Novelli P and Lambkin R (2003). "Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors." Clinical microbiology and infection9(1) : 1-14.

153. Paget WJ and Aguilera J-F (2001). "Les plans de lutte contre la pandémie de grippe en Europe. (Influenza pandemic planning in Europe)." Euro surveillance6(9) : 136-140.

154. Parrish CR and Kawaoka Y (2005). "The origins of new pandemic viruses : the acquisition of new host ranges by canine parvovirus and influenza A viruses." Annu Rev Microbiol59 : 553-86.

155. Payungporn S, Chutinimitkul S, Chaisingh A, Damrongwantanapokin S, Buranathai C, Amonsin A, Theamboonlers A and Poovorawan Y (2006). "Single step multiplex real-time RT-PCR for H5N1 influenza A virus detection." J Virol Methods 131(2) : 143-147.

156. Peiris M, Yuen KY, Leung CW, Chan KH, Ip PL, Lai RW, Orr WK and Shortridge KF (1999). "Human infection with influenza H9N2." Lancet 354(9182) : 916-7.

157. Perdue ML, Suarez DL, Van RK and Pensaert M (2000). "Structural features of the avian influenza virus hemagglutinin that influence virulence." Veterinary microbiology : (Amsterdam)74(1-2) : 77-86.

158. Playford EG and Dwyer DE (2002). "Laboratory diagnosis of influenza virus infection." Pathology : (Sydney)34(2) : 115-125.

159. Puthavathana P, Auewarakul P, Charoenying PC, Sangsiriwut K, Pooruk P, Boonnak K, Khanyok R, Thawachsupa P, Kijphati R and Sawanpanyalert P (2005). "Molecular characterization of the complete genome of human influenza H5N1 virus isolates from Thailand." J Gen Virol 86(Pt 2) : 423-33.

160. Puzelli S, Di Trani L, Fabiani C, Campitelli L, De Marco MA, Capua I, Aguilera JF, Zambon M and Donatelli I (2005). "Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003." J Infect Dis192(8) : 1318-22.

161. Quirk M (2004). "Zoo tigers succumb to avian influenza." Lancet Infect Dis4(12) : 716.

162. Quirk M (2005). "Avian influenza vaccine clinical trial begins in USA." Lancet Infect Dis5(5) : 266.

163. Rimmelzwaan GF, Kuiken T, van Amerongen G, Bestebroer TM, Fouchier RA and Osterhaus AD (2003). "A primate model to study the pathogenesis of influenza A (H5N1) virus infection." Avian Dis47(3 Suppl) : 931-3.

164. Roberts NA (2001). "Anti-influenza drugs and neuraminidase inhibitors." Progress in drug research56 : 195-237.

165. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ and Katz JM (1999). "Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays." J Clin Microbiol37(4) : 937-43.

166. Rowe T, Cho DS, Bright RA, Zitzow LA and Katz JM (2003). "Neurological manifestations of avian influenza viruses in mammals." Avian Dis47(3 Suppl) : 1122-6.

167. Russell CJ and Webster RG (2005). "The genesis of a pandemic influenza virus." Cell123(3) : 368-71.

168. Savarino A (2005). "Expanding the frontiers of existing antiviral drugs : Possible effects of HIV-1 protease inhibitors against SARS and avian influenza." J Clin Virol34(3) : 170-8.

169. Schultsz C, Dong VC, Chau NV, Le NT, Lim W, Thanh TT, Dolecek C, de Jong MD, Hien TT and Farrar J (2005). "Avian influenza H5N1 and healthcare workers." Emerg Infect Dis 11(7) : 1158-9.

170. Seo SH, Hoffmann E and Webster RG (2002). "Lethal H5N1 influenza viruses escape host anti-viral cytokine responses." Nat Med8(9) : 950-4.

171. Seo SH, Hoffmann E and Webster RG (2004). "The NS1 gene of H5N1 influenza viruses circumvents the host anti-viral cytokine responses." Virus Res103(1-2) : 107-13.

172. Shengqiang LI, Chongguang LIU, Klimov A, Subbarao K, Perdue ML, Delia MO, Yaying JI, Woods L, Hietala S and Bryant M (1999). "Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses." The Journal of infectious diseases179(5) : 1132-1138.

173. Shinya K, Hamm S, Hatta M, Ito H, Ito T and Kawaoka Y (2004). "PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice." Virology320(2) : 258-66.

174. Shinya K, Hatta M, Yamada S, Takada A, Watanabe S, Halfmann P, Horimoto T, Neumann G, Kim JH, Lim W, Guan Y, Peiris M, Kiso M, Suzuki T, Suzuki Y and Kawaoka Y (2005). "Characterization of a human H5N1 influenza A virus isolated in 2003." J Virol79(15) : 9926-32.

175. Sidwell RW, Bailey KW, Wong MH, Barnard DL and Smee DF (2005). "In vitro and in vivo influenza virus-inhibitory effects of viramidine." Antiviral Res68(1) : 10-7.

176. Sims LD, Domenech J, Benigno C, Kahn S, Kamata A, Lubroth J, Martin V and Roeder P (2005). "Origin and evolution of highly pathogenic H5N1 avian influenza in Asia." Vet Rec157(6) : 159-64.

177. Stegeman A, Bouma A, Elbers AR, de Jong MC, Nodelijk G, de Klerk F, Koch G and van Boven M (2004). "Avian influenza A virus (H7N7) epidemic in The Netherlands in 2003 : course of the epidemic and effectiveness of control measures." J Infect Dis190(12) : 2088-95.

178. Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E and Zambon M (2003). "Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population." Vaccine21(15) : 1687-93.

179. Stephenson I, Wood JM, Nicholson KG and Zambon MC (2003). "Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin." J Med Virol70(3) : 391-8.

180. Strikas RA, Wallace GS and Myers MG (2002). "Influenza pandemic preparedness action plan for the United States : 2002 Update." Clinical infectious diseases35(5) : 590-596.

181. Suarez DL, Van RK and Pensaert M (2000). "Evolution of avian influenza viruses." Veterinary microbiology : (Amsterdam)74(1-2) : 15-27.

182. Subbarao K, Chen H, Swayne D, Mingay L, Fodor E, Brownlee G, Xu X, Lu X, Katz J, Cox N and Matsuoka Y (2003). "Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics." Virology305(1) : 192-200.

183. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda K and Cox N (1998). "Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness." Science : (Washington, D.C.) 279(5349) : 393-396.

184. Sun C, Huang H, Feng M, Shi X, Zhang X and Zhou P (2006). "A novel class of potent influenza virus inhibitors : Polysubstituted acylthiourea and its fused heterocycle derivatives." Bioorg Med Chem Lett16(1) : 162-6.

185. Suzuki Y (2001). "Host mediated variation and receptor binding specificity of influenza viruses." Adv Exp Med Biol491 : 445-51.

186. Suzuki Y (2005). "Sialobiology of influenza : molecular mechanism of host range variation of influenza viruses." Biol Pharm Bull28(3) : 399-408.

187. Suzuki Y, Ito T, Suzuki T, Holland RE, Jr., Chambers TM, Kiso M, Ishida H and Kawaoka Y (2000). "Sialic acid species as a determinant of the host range of influenza A viruses." J Virol74(24) : 11825-31.

188. Tanaka H, Park C-H, Ninomiya A, Ozaki H, Takada A, Umemura T and Kida H(2003). "Neurotropism of the 1997 Hong Kong H5N1 influenza virus in mice." Veterinary microbiology : (Amsterdam)95(1-2) : 1-13.

189. Taubenberger JK, Reid AH, Krafft AE, Bijwaard KE and Fanning TG (1997). "Initial genetic characterization of the 1918 "Spanish" influenza virus." Science : (Washington, D.C.)275(5307) : 1793-1796.

190. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G and Fanning TG(2005). "Characterization of the 1918 influenza virus polymerase genes." Nature437(7060) : 889-93.

191. Thanawongnuwech R, Amonsin A, Tantilertcharoen R, Damrongwatanapokin S, Theamboonlers A, Payungporn S, Nanthapornphiphat K, Ratanamungklanon S, Tunak E, Songserm T, Vivatthanavanich V, Lekdumrongsak T, Kesdangsakonwut S, Tunhikorn S and Poovorawan Y (2005). "Probable tiger-to-tiger transmission of avian influenza H5N1." Emerg Infect Dis 11(5) : 699-701.

192. Thornley M (2004). "Avian influenza ravages Thai tigers." Aust Vet J82(11) : 652.

193. Tompkins SM, Lo CY, Tumpey TM and Epstein SL (2004). "Protection against lethal influenza virus challenge by RNA interference in vivo." Proc Natl Acad Sci U S A101(23) : 8682-6.

194. Tran TH, Nguyen TL, Nguyen TD, Luong TS, Pham PM, Nguyen VC, Pham TS, Vo CD, Le TQ, Ngo TT, Dao BK, Le PP, Nguyen TT, Hoang TL, Cao VT, Le TG, Nguyen DT, Le HN, Nguyen KT, Le HS, Le VT, Christiane D, Tran TT, Menno de J, Schultsz C, Cheng P, Lim W, Horby P and Farrar J (2004). "Avian influenza A (H5N1) in 10 patients in Vietnam." N Engl J Med 350(12) : 1179-88.

195. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W and Katz JM (2001). "Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans." Vaccine19(13-14) : 1732-7.

196. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P and Garcia-Sastre A (2005). "Characterization of the reconstructed 1918 Spanish influenza pandemic virus." Science 310(5745) : 77-80.

197. Ungchusak K, Auewarakul P, Dowell SF, Kitphati R, Auwanit W, Puthavathana P, Uiprasertkul M, Boonnak K, Pittayawonganon C, Cox NJ, Zaki SR, Thawatsupha P, Chittaganpitch M, Khontong R, Simmerman JM and Chunsutthiwat S (2005). "Probable person-to-person transmission of avian influenza A (H5N1)." N Engl J Med 352(4) : 333-40.

198. Uyeki TM, Chong YH, Katz JM, Lim W, Ho YY, Wang SS, Tsang TH, Au WW, Chan SC, Rowe T, Hu-Primmer J, Bell JC, Thompson WW, Bridges CB, Cox NJ, Mak KH and Fukuda K (2002). "Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999." Emerg Infect Dis 8(2) : 154-9.

199. Van DWS and Manuguerra JC (2000). "Bases moléculaires de la variabilité et diffusion des virus grippaux. (Molecular basis of influenza virus variability and diffusion)." L'Eurobiologiste : (Paris)34(247) : 38-41.

DE 200 à 249

200. Wales JR, Baird MA, Davies NM and Buchan GS (2005). "Fusing subunit antigens to interleukin-2 and encapsulating them in liposomes improves their antigenicity but not their protective efficacy." Vaccine23(17-18) : 2339-41.

201. Walker JA and Kawaoka Y (1993). "Importance of conserved amino acids at the cleavage site of the haemagglutinin of a virulent avian influenza A virus." Journal of general virology74(p.2) : 311-314.

202. Ward P, Small I, Smith J, Suter P and Dutkowski R (2005). "Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic." J Antimicrob Chemother55 Suppl 1 : i5-i21.

203. Watson KG, Cameron R, Fenton RJ, Gower D, Hamilton S, Jin B, Krippner GY, Luttick A, McConnell D, MacDonald SJ, Mason AM, Nguyen V, Tucker SP and Wu WY (2004). "Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase." Bioorg Med Chem Lett 14(6) : 1589-92.

204. Webby RJ, Perez DR, Coleman JS, Guan Y, Knight JH, Govorkova EA, McClain-Moss LR, Peiris JS, Rehg JE, Tuomanen EI and Webster RG (2004). "Responsiveness to a pandemic alert : use of reverse genetics for rapid development of influenza vaccines." Lancet363(9415) : 1099-103.

205. WHO Global Influenza Program (2005). "Evolution of H5N1 Avian Influenza Viruses in Asia." Emerg Infect Dis11(10).

206. Wiwanitkit V (2005). "Diarrhoea as a presentation of bird flu infection : a summary on its correlation to outcome in Thai cases." Gut54(10) : 1506.

207. Wong JP, Nagata LP, Christopher ME, Salazar AM and Dale RM (2005). "Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs." Vaccine23(17-18) : 2266-8.

208. Wong JP, Yang H, Nagata L, Kende M, Levy H, Schnell G and Blasetti K (1999). "Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC." Vaccine17(13-14) : 1788-95.

209. Xu X, Lindstrom SE, Shaw MW, Smith CB, Hall HE, Mungall BA, Subbarao K, Cox NJ and Klimov A (2004). "Reassortment and evolution of current human influenza A and B viruses." Virus Res103(1-2) : 55-60.

210. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG and Govorkova EA (2005). "Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility." Antimicrob Agents Chemother49(10) : 4075-84.

211. Yen HL, Monto AS, Webster RG and Govorkova EA (2005). "Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice." J Infect Dis192(4) : 665-72.

212. Yuen KY and Wong SS (2005). "Human infection by avian influenza A H5N1." Hong Kong Med J11(3) : 189-99.

213. Zambon MC (2001). "The pathogenesis of influenza in humans." Reviews in medical virology11(4) : 227-241.

214. Zhou N, He S, Zhang T, Zou W, Shu L, Sharp GB and Webster RG (1996). "Influenza infection in humans and pigs in southeastern China." Archives of virology141(3-4) : 649-661.

215. Zurbriggen R (2003). "Immunostimulating reconstituted influenza virosomes." Vaccine21(9-10) : 921-4.

Grippe aviaire et transmission chez l'homme (2006) Delvallée/Documentation

Sommaire

Documentation

Organismes internationaux et nationaux de surveillance

Liens utiles

Références bibliographiques

De 1 à 49

De 50 à 99

De 100 à 149

DE 150 à 199

DE 200 à 249

Menu de navigation

Affichages

Outils personnels

Navigation

Rechercher

Outils